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FDA APPROVES NEW DIABETES/HEART DRUG STUDIED AT UM 
M ISSOULA-
The Food and Drug Administration recently approved a new drug for Type II diabetes 
that has been under investigation for several years in pharmaceutical sciences labs at The 
University of Montana.
The drug, Actos or pioglitazone hydrochloride, also may reduce the risk of 
cardiovascular complications, which is extremely important in the treatment of diabetes.
“The risk of heart disease in diabetics is much greater than in normal individuals,” said 
pharmaceutical sciences Professor Vernon Grund, principal investigator on the project. 
“Diabetes is not merely a disorder involving blood sugar. It also involves blood fats and makes 
the fat in your blood -  LDL cholesterol -- more easily stick in the arteries. Diabetes increases 
the risk of heart attacks and strokes just as smoking and high blood pressure do. ”
Since 1997 the FDA has approved three new drugs of the Actos class that are targeted 
for noninsulin-dependent diabetics who gain weight and suffer from insulin resistance, Grund 
said. Insulin resistance is closely associated with obesity, high blood pressure and high lipid 
levels, all of which are risk factors for heart disease and stroke, he said.
Grund conducted the studies on special Zucker Diabetic Fatty rats that rapidly gain
-more-
weight and spontaneously develop insulin resistance and Type II diabetes. Blood fat levels in 
these animals, especially triglycerides and cholesterol, also soar to levels as much as seven 
times the normal. Grund found that pioglitazone normalizes triglycerides and blood sugar after 
only two weeks of treatment. Blood cholesterol levels also fall even though the rats are quite 
obese.
Grund’s research was sponsored by the American Heart Association. Others working 
on the project included pharmaceutical sciences Associate Professor Jerry Smith and graduate 
student Heather Fraser. Grund’s original project, “Pharmacologic Intervention With 
Cardiovascular Complications of Type II Diabetes,” was funded by the association’s local 
affiliate in 1994-96.
Actos will be marketed in the United States by Takeda Chemical Industries Ltd. of 
Japan in a joint agreement with Eli Lilly and Co. of Indianapolis. The Upjohn Company, the 
U.S. company originally affiliated with Takeda, supported Grund’s research on the drug in 
1992 but pulled out of its agreement when early reports in animal studies indicated that the 
drug may cause cardiac enlargement. In his studies, Grund found that the drug had no bad 
effects on cardiac performance despite slight increases in heart size.
While this new drug is good news for diabetics, Grund said there still is no substitute 
for proper exercise, nutrition and weight control in the fight against heart disease and diabetes. 
A runner and fitness buff himself, he has only six states to go to realize his dream of running 
in all 50 states.
Grund was recently elected to a two-year term as president of the American Heart 
Association’s Northwest Affiliate, which takes in Washington, Oregon, Alaska, Idaho and
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Montana. He’s chaired UM’s pharmaceutical sciences department since 1992, and under his 
leadership it has increased research funding more than seven-fold to well over $1 million 
annually. The department also is closely affiliated with The International Heart Institute of 
Montana Foundation.
UM is a major sponsor of this year’s American Heart Walk to be held Saturday, Sept. 
18, at Southgate Mall. Check-in will begin at 8 a.m. in the J.C. Penney court. The walk raises 
money to support, education and community service.
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